Dr. Fuguo Jiang
The University of Texas MD Anderson Cancer Center
Department of Cancer Biology
CRISPR/Cas system is a microbial nucleic acid-guided immune system that shares similar functions with RNA interference in eukaryotes. It has recently been harnessed to a versatile and powerful tool for genome editing and gene regulation in many eukaryotic organisms and shows great promise in treating human genetic disorders from cancer to neurodegeneration.
My lab at MD Anderson Cancer Center is therefore focused on the elucidation of the molecular mechanism of the RNA-guided DNA endonuclease Cas9 from the Type II CRISPR system and many other effector Cas proteins that are potentially useful for DNA/RNA editing and detection in human cancer diseases. My current research also involves understanding the molecular mechanism by which viral anti-CRISPR proteins inhibit CRISPR immunity. This research platform is based on the notion that we need to improve CRISPR-based cancer treatments by reducing any potential off-target effects.
In addition to continuing to pioneer CRISPR mechanistic studies to further support CRISPR tool development for cancer therapy, my lab is also interested in studying the roles of regulatory RNAs and chromatin deregulation that lead to tumorigenesis and metastasis using integrative structural biology approach combining biochemical, biophysical, and structural biology methods (X-ray, cryo-SPA/ET).